Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $53,394.73 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 64,331 shares of the business’s stock in a transaction on Friday, November 21st. The shares were sold at an average price of $0.83, for a total transaction of $53,394.73. Following the completion of the sale, the insider directly owned 5,257,105 shares in the company, valued at $4,363,397.15. This trade represents a 1.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Tuesday, November 25th, Bioventures 2014 L.P. Mpm sold 42,533 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.92, for a total transaction of $39,130.36.
• On Monday, November 24th, Bioventures 2014 L.P. Mpm sold 88,802 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total transaction of $87,025.96.
• On Thursday, November 20th, Bioventures 2014 L.P. Mpm sold 41,152 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total transaction of $36,625.28.
• On Wednesday, November 19th, Bioventures 2014 L.P. Mpm sold 66,324 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $62,344.56.
• On Tuesday, November 18th, Bioventures 2014 L.P. Mpm sold 52,627 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.93, for a total transaction of $48,943.11.
• On Monday, November 17th, Bioventures 2014 L.P. Mpm sold 57,061 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.95, for a total value of $54,207.95.
• On Friday, November 14th, Bioventures 2014 L.P. Mpm sold 61,640 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total value of $57,325.20.
• On Thursday, November 13th, Bioventures 2014 L.P. Mpm sold 90,951 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total value of $89,131.98.
• On Wednesday, November 12th, Bioventures 2014 L.P. Mpm sold 40,669 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total value of $44,329.21.
• On Tuesday, November 11th, Bioventures 2014 L.P. Mpm sold 55,810 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.14, for a total value of $63,623.40.

Werewolf Therapeutics Stock Up 7.3%

Shares of NASDAQ:HOWL opened at $0.98 on Friday. The company’s fifty day moving average is $1.49 and its 200-day moving average is $1.33. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. Werewolf Therapeutics, Inc. has a 52 week low of $0.60 and a 52 week high of $2.38. The company has a market capitalization of $47.42 million, a PE ratio of -0.60 and a beta of 0.72.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. Equities research analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. Zacks Research cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. JMP Securities lowered their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. Finally, Bank of America cut their price target on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Werewolf Therapeutics has an average rating of “Moderate Buy” and an average price target of $7.75.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Quadrature Capital Ltd bought a new position in Werewolf Therapeutics in the 2nd quarter valued at $28,000. Qube Research & Technologies Ltd acquired a new position in shares of Werewolf Therapeutics during the second quarter valued at $48,000. Nuveen LLC acquired a new position in shares of Werewolf Therapeutics during the first quarter valued at $71,000. AQR Capital Management LLC bought a new position in Werewolf Therapeutics in the first quarter valued at about $79,000. Finally, Y Intercept Hong Kong Ltd bought a new position in Werewolf Therapeutics in the second quarter valued at about $92,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.